Life Sciences

Eli Lilly to pay $62M for improperly marketing Zyprexa

Pharma Compliance Alert, October 8, 2008

Eli Lilly agreed to pay $62 million to 32 states and the District of Columbia to resolve allegations it improperly marketed its antipsychotic medication Zyprexa, according to a company statement.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   
    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

  • Needlestick Prevention Training Video

    Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...

Most Popular